Last updated: May 31, 2026
- API manufacturers selling HCTZ as a commodity generic API
- Contract manufacturing organizations (CMOs) that convert HCTZ API into tablets for different NDA/ANDA holders
- Packaging and distribution providers for OTC and generic channels
How to structure supplier qualification for HCTZ
- Verify DMF/CEP coverage for the specific polymorph and particle-size specs used by the ANDA
- Confirm impurity profile controls (process-related impurities) against the ANDA’s validated specifications
- Confirm stability data for the intended tablet formulation and packaging system
Suppliers for quinapril hydrochloride API: who manufactures QnHCl
Quinapril hydrochloride is an ACE inhibitor API with long-standing generic availability. API supply is concentrated among major global API producers and toll manufacturers able to maintain tight impurity and stereochemical/process controls required for ANDA approval and bioequivalence consistency.
Key supplier archetypes
- Dedicated ACE-inhibitor API producers with recurring supply to multiple ANDA portfolios
- CMOs with tablet-compression lines qualified for moisture-sensitive formulation constraints
- Finish-and-pack plants that buy QnHCl API and produce strength-specific tablets
Qualification points for QnHCl
- Impurity set alignment with the ANDA’s commercial specs (key degradants depend on formulation moisture and storage)
- Salt form confirmation for quinapril hydrochloride (hydrochloride salt integrity)
- Consistency of active particle size distribution to avoid dissolution and BE drift
How do HCTZ and quinapril hydrochloride supply chains differ in practice?
HCTZ is often treated as a high-volume commodity API with many qualified sources, which compresses supplier switching friction. QnHCl supply can be more sensitive to supplier-specific impurity control, and some ANDA holders keep fewer approved sources to avoid revalidation burden.
API vs finished-dose supply: who sells what?
For both actives, procurement typically splits into:
- API supply to ANDA holders or CMOs
- Tablet manufacturing by CMO or finished-dose manufacturer
- Secondary packaging by another vendor or in-house
This makes “supplier of record” highly contract-specific. For procurement and litigation risk mapping, the more reliable artifact is ANDA-linked regulatory documentation (DMFs and manufacturer-of-record) rather than marketing brochures.
Which companies supply hydrochlorothiazide and quinapril combinations?
Fixed-dose combinations (commonly HCTZ/quinapril) usually involve:
- An API supply agreement for each active ingredient
- A formulation and tableting contract under the ANDA holder or CMO
- A packaging and distribution contract tied to the labeled NDC
Supplier selection usually follows ANDA manufacturing authorizations and the ANDA holder’s approved vendor list for raw materials and packaging components.
What filings determine “true suppliers” for HCTZ and quinapril?
The practical “supplier truth” is in the regulatory ecosystem:
- DMF holders (API manufacturing site and process)
- ANDA manufacturer-of-record (finish plant)
- Labeler/manufacturer on FDA labeling and distribution paperwork
- Ongoing annual reports tied to the ANDA
What are typical risks in sourcing HCTZ and QnHCl APIs?
- Quality system gaps across multi-site suppliers
- Impurity excursions driven by feedstock or process variability
- Regulatory audit findings that force changes in approved sites
- Lead-time volatility due to seasonal demand and single-site bottlenecks
Commercial supplier strategy for both drugs
- Maintain dual sourcing for HCTZ wherever allowed by the ANDA quality system.
- For QnHCl, build redundancy across at least two approved DMF-linked sources or two qualified commercial lots from separate sites, depending on the ANDA holder’s change-control burden.
- Qualify packaging formats early because moisture control can affect shelf-life for ACE inhibitor tablets.
Key Takeaways
- HCTZ and quinapril hydrochloride have broad global API availability, but “supplier identity” for a specific product is contract and filing specific.
- For actionable procurement, focus on DMF-linked API manufacturing sites and ANDA-linked finish manufacturing authorizations rather than generic supplier lists.
- Sourcing HCTZ is typically lower switching-friction; QnHCl can carry higher impurity- and stability-driven qualification sensitivity.
- Build dual or multi-source supply plans, with change-control and audit readiness aligned to the ANDA holder’s approved vendor list.
FAQs
- How can I identify the actual API manufacturers for hydrochlorothiazide in a specific ANDA?
- What DMF-backed supplier documentation is needed to qualify quinapril hydrochloride API?
- Which quality tests are most likely to trigger batch rejection for HCTZ tablets?
- How do impurity profiles differ between hydrochlorothiazide and quinapril hydrochloride API sourcing?
- What supply-chain bottlenecks most often affect ACE inhibitor tablet manufacturing in the U.S. generic market?
References
No sources were provided in the prompt, and no external datasets (FDA Orange Book, OpenFDA, DMF indexes, or company-specific disclosures) were supplied to support an accurate named-supplier list.
